Twice-monthly administration of a lower dose of epoetin beta pegol can maintain adequate hemoglobin levels in hemodialysis patients

Therapeutic Apheresis and Dialysis

Volumn 19, Issue 2, 2015, Pages 138-143

  Morikami, Yuki ^a   Fujimori, Akira ^a   Okada, Shioko ^a   Kumei, Mai ^a   Mizobuchi, Noriko ^a   Sakai, Makoto ^a  

^a KOHNAN HOSPITAL   (Japan)

Author keywords

Anemia; Epoetin beta pegol; Ferritin; Hemodialysis; Hepcidin 25

Indexed keywords

CONTINUOUS ERYTHROPOIESIS RECEPTOR ACTIVATOR; FERRITIN; HEMOGLOBIN; HEPCIDIN; RECOMBINANT ERYTHROPOIETIN; TRANSFERRIN; ERYTHROPOIETIN; MACROGOL DERIVATIVE; RECOMBINANT PROTEIN;

AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; FEMALE; HEMODIALYSIS PATIENT; HEMOGLOBIN BLOOD LEVEL; HUMAN; IRON METABOLISM; MALE; PRIORITY JOURNAL; RETICULOCYTE COUNT; BLOOD; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG EFFECTS; RENAL REPLACEMENT THERAPY; TREATMENT OUTCOME;

AGED; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; ERYTHROPOIETIN; FEMALE; HEMOGLOBINS; HUMANS; MALE; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; RENAL DIALYSIS; TREATMENT OUTCOME;

EID: 84926451414     PISSN: 17449979     EISSN: 17449987     Source Type: Journal    
DOI: 10.1111/1744-9987.12248     Document Type: Article

References (20)

1. Regidor DL, Kopple JD, Kovesdy CP etal. Associations between changes in hemoglobin and administered erythropoiesis-stimulating agent and survival in hemodialysis patients. J Am Soc Nephrol 2006;17:1181-1191.
2. Macdougall IC, Padhi D, Jang G. Pharmacology of darbepoetin alfa. Nephrol Dial Transplant 2007;22(Suppl 4):iv2-iv9.
3. Akizawa T, Koshikawa S, Iwasaki M. Darbepoetin alfa effectively maintains hemoglobin concentrations at extended dose intervals relative to intravenous rHuEPO in Japanese dialysis patients. Ther Apher Dial 2007;11:220-226.
4. Fukuhara S, Akizawa T, Morita S, Koshikawa S. Quality of life improvements in dialysis patients receiving darbepoetin alfa. Ther Apher Dial 2008;12:72-77.
5. Shoji S, Inaba M, Tomosugi N etal. Greater potency of darbepoetin-alpha than erythropoietin in suppression of serum hepcidin-25 and utilization of iron for erythropoiesis in hemodialysis patients. Eur J Haematol 2013;90:237-244.
6. Hayashi T, Kobayashi T, Kukita K etal. Pharmacokinetics of C.E.R.A. (Continuous Erythropoietin receptor Activator) in Japanese chronic kidney disease patients on dialysis. Jpn Pharmacol Ther 2010;38:1175-1190.
7. Levin NW, Fishbane S, Canedo FV etal. Intravenous methoxy polyethylene glycol-epoetin beta for haemoglobin control in patients with chronic kidney disease who are on dialysis: a randomised non-inferiority trial (MAXIMA). Lancet 2007;370:1415-1421.
8. Morikami Y, Fujimori A, Okada S, Kumei M, Mizobuchi N, Sakai M. Comparison of 2-week versus 4-week dosing intervals of epoetin beta pegol on erythropoiesis and iron metabolism in hemodialysis patients. Ther Apher Dial 2014;18:414-420.
9. Murao N, Ishigai M, Yasuno H, Shimonaka Y, Aso Y. Simple and sensitive quantification of bioactive peptides in biological matrices using liquid chromatography/selected reaction monitoring mass spectrometry coupled with trichloroacetic acid clean-up. Rapid Commun Mass Spectrom 2007;21:4033-4038.
10. Alfrey CP, Fishbane S. Implications of neocytolysis for optimal management of anaemia in chronic kidney disease. Nephron Clin Pract 2007;106:c149-156.
11. Trial J, Rice L, Alfrey CP. Erythropoietin withdrawal alters interactions between young red blood cells, splenic endothelial cells, and macrophages: an in vitro model of neocytolysis. J Investig Med 2001;49:335-345.
12. Kuragano T, Itoh K, Shimonaka Y etal. Hepcidin as well as TNF-alpha are significant predictors of arterial stiffness in patients on maintenance hemodialysis. Nephrol Dial Transplant 2011;26:2663-2667.
13. Hasuike Y, Nonoguchi H, Tokuyama M etal. Serum ferritin predicts prognosis in hemodialysis patients: the Nishinomiya study. Clin Exp Nephrol 2010;14:349-355.
14. Ghoti H, Rachmilewitz EA, Simon-Lopez R etal. Evidence for tissue iron overload in long-term hemodialysis patients and the impact of withdrawing parenteral iron. Eur J Haematol 2012;89:87-93.
15. Pigeon C, Ilyin G, Courselaud B etal. A new mouse liver-specific gene, encoding a protein homologous to human antimicrobial peptide hepcidin, is overexpressed during iron overload. J Biol Chem 2001;276:7811-7819.
16. Babitt JL, Lin HY. Molecular mechanisms of hepcidin regulation: implications for the anemia of CKD. Am J Kidney Dis 2010;55:726-741.
17. Nemeth E, Tuttle MS, Powelson J etal. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 2004;306:2090-2093.
18. Kuragano T, Shimonaka Y, Kida A etal. Determinants of hepcidin in patients on maintenance hemodialysis: role of inflammation. Am J Nephrol 2010;31:534-540.
19. Dallalio G, Law E, Means RT Jr. Hepcidin inhibits in vitro erythroid colony formation at reduced erythropoietin concentrations. Blood 2006;107:2702-2704.
20. Sasaki Y, Noguchi-Sasaki M, Yasuno H, Yorozu K, Shimonaka Y. Erythropoietin stimulation decreases hepcidin expression through hematopoietic activity on bone marrow cells in mice. Int J Hematol 2012;96:692-700.